As South Africa temporarily halts the AstraZeneca vaccine out of concern it doesn't protect from variants, scientists are racing to understand how new variants will affect immunity.
The furniture retailer bowed to pressure to hand back wage subsidies after a 60 per cent profit jump; Australia could see tourists by 2022. Follow updates here.
Covid-19 Prédire l évolution du virus pour adapter les vacci sciencesetavenir.fr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencesetavenir.fr Daily Mail and Mail on Sunday newspapers.
According to Johnson & Johnson’s press release, the company’s single shot was 85 percent effective in preventing severe forms of the disease across the 44,000 people enrolled in each of three trials in the United States, Latin America, and South Africa. But when it came to fending off more mild cases of coronavirus infection, the vaccine worked best in the US, where it was 72 percent protective compared to just 57 percent in South Africa. (The shot’s efficacy in Latin America was 66 percent.)
It was the same story with Novavax, a much smaller, Maryland-based company. In its 15,000-person United Kingdom trial, the vaccine demonstrated 89 percent efficacy against mild, moderate, and severe cases of Covid-19; in the company’s smaller study in South Africa, the efficacy rate fell to about 50 percent.
The COVID-19 virus has been mutating since it was first discovered, but scientists are racing to understand how new variants like B.1.1.7 will affect immunity and vaccines.